Targeting the human epidermal growth factor receptor 2 (HER2) expressed on tumor cells with the anti-HER2 antibody trastuzumab is an established therapy for the treatment of HER2-positive breast cancers (159, 160). Here, ERBB2 is linked to neoplasm.